CDH1 and breast cancer: One possible approach would require only two prerequisites: (i) assessment of the E-cadherin IHC status in all BCs considered as ILC based on histomorphology, and (ii) definition of key criteria that qualify a given BC as ILC, if E-cadherin expression is not entirely lost.